Tech Company Financing Transactions
Excision BioTherapeutics Funding Round
On 9/7/2017, Excision BioTherapeutics received $10 million in Seed financing from ARTIS Ventures and private investors.
Transaction Overview
Company Name
Announced On
9/7/2017
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Seed
Investors
ARTIS Ventures (Lead Investor) (Stuart Peterson)
Proceeds Purpose
The investment will enable the company to enter into human clinical trials with its HIV-1 targeted CRISPR platform, giving Excision BioTherapeutics the first effort to fully remove/excise the HIV-1 genome from all human cells and tissues.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
988 Market St.
San Francisco, CA 94102
USA
San Francisco, CA 94102
USA
Phone
Undisclosed
Website
Email Address
Overview
Excision BioTherapeutics Inc. is a life science company focused on the development and commercialization of advanced gene editing therapeutics for the treatment and eradication of life-threatening disease caused by neurotropic viruses (viral infections).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniel Dornbusch
Chief Medical Officer
Revati Shreeniwas
Chief Scientific Officer
TJ Cradick
Chief Scientific Officer
Kamel Khalili
VP - Bus. Development
Michael Aberman
VP - R & D
Jenn Gordon
VP - Regulatory Affairs
Patricia Williams
Browse more venture capital transactions:
Prev: 9/7/2017: Akonni Biosystems venture capital transaction
Next: 9/7/2017: Keepe venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We record all VC transactions involving tech companies. All VC database entries on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs